Kymera Therapeutics (KYMR) Stock Forecast & Price Target

Compare

345 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KYMR Analyst Ratings

Strong Buy

17 Buy

0 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Kymera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$61.33

▲(40.47% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $61.33 with a high forecast of $70.00 and a low forecast of $53.00. The average price target represents a 40.47% change from the last price of $43.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","71":"$71","35.75":"$35.8","47.5":"$47.5","59.25":"$59.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$53.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,35.75,47.5,59.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.44,46.40615384615384,48.37230769230769,50.33846153846154,52.30461538461538,54.27076923076923,56.23692307692308,58.20307692307692,60.169230769230765,62.135384615384616,64.10153846153847,66.06769230769231,68.03384615384616,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.44,45.739230769230765,47.03846153846153,48.33769230769231,49.636923076923075,50.93615384615384,52.23538461538461,53.53461538461538,54.83384615384615,56.13307692307692,57.43230769230769,58.73153846153846,60.030769230769224,{"y":61.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.44,45.098461538461535,45.75692307692307,46.41538461538461,47.073846153846155,47.73230769230769,48.39076923076923,49.04923076923077,49.707692307692305,50.36615384615384,51.02461538461539,51.683076923076925,52.34153846153846,{"y":53,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.49,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.36,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$70.00

Average Price Target$61.33

Lowest Price Target$53.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

14.52%

Upside

Reiterated

06/25/25

Kymera Therapeutics benefits from strong technical momentum and strategic corporate partnerships, which enhance its growth outlook despite current financial challenges. The company's substantial cash reserves and promising pipeline developments further support future potential, although the negative cash flow and earnings remain significant risks.

Mayank MamtaniB.Riley Financial

B.Riley Financial

$60

Buy

37.43%

Upside

Initiated

07/30/25

Kymera Therapeutics transferred with Buy rating at B. RileyKymera Therapeutics transferred with Buy rating at B. Riley

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$70→$65

Buy

48.88%

Upside

Reiterated

07/07/25

Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

Judah FrommerMorgan Stanley

Morgan Stanley

$79→$70

Buy

60.33%

Upside

Initiated

07/03/25

Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships

Jeet MukherjeeBTIG

BTIG

$55→$59

Buy

35.14%

Upside

Reiterated

07/01/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), Nektar Therapeutics (NKTR)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$68

Buy

55.75%

Upside

Reiterated

06/30/25

Tazeen AhmadBank of America Securities

Bank of America Securities

$51→$54

Buy

23.68%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Gilead Sciences (GILD)

Richard NewitterTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/26/25

Truist Financial Remains a Buy on Kymera Therapeutics (KYMR)

Derek ArchilaWells Fargo

Wells Fargo

$57→$53

Buy

21.39%

Upside

Reiterated

06/26/25

Optimistic Outlook for Kymera Therapeutics Amid Strategic Partnerships and Strong KT-621 Prospects

Andrew FeinH.C. Wainwright

H.C. Wainwright

$54→$60

Buy

37.43%

Upside

Reiterated

06/26/25

Kymera Therapeutics price target raised to $60 from $54 at H.C. WainwrightKymera Therapeutics price target raised to $60 from $54 at H.C. Wainwright

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/26/25

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Jeff JonesOppenheimer

Oppenheimer

$56→$53

Buy

21.39%

Upside

Reiterated

06/26/25

Kymera Therapeutics price target lowered to $53 from $56 at OppenheimerKymera Therapeutics price target lowered to $53 from $56 at Oppenheimer

Faisal KhurshidLeerink Partners

Leerink Partners

$60

Buy

37.43%

Upside

Reiterated

06/25/25

Leerink Partners Remains a Buy on Kymera Therapeutics (KYMR)

Kelly ShiJefferies

Jefferies

$66→$64

Buy

46.59%

Upside

Reiterated

06/25/25

Kymera Therapeutics (KYMR) Receives a Buy from Jefferies

Eliana MerleUBS

UBS

$70

Buy

60.33%

Upside

Reiterated

06/03/25

UBS Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$50

Hold

14.52%

Upside

Reiterated

06/25/25

Mayank MamtaniB.Riley Financial

B.Riley Financial

$60

Buy

37.43%

Upside

Initiated

07/30/25

Kymera Therapeutics transferred with Buy rating at B. RileyKymera Therapeutics transferred with Buy rating at B. Riley

Leah R. CannBrookline Capital Markets

Brookline Capital Markets

$70→$65

Buy

48.88%

Upside

Reiterated

07/07/25

Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

Judah FrommerMorgan Stanley

Morgan Stanley

$79→$70

Buy

60.33%

Upside

Initiated

07/03/25

Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships

Jeet MukherjeeBTIG

BTIG

$55→$59

Buy

35.14%

Upside

Reiterated

07/01/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), Nektar Therapeutics (NKTR)

Alex Thompson CFAStifel Nicolaus

Stifel Nicolaus

$68

Buy

55.75%

Upside

Reiterated

06/30/25

Tazeen AhmadBank of America Securities

Bank of America Securities

$51→$54

Buy

23.68%

Upside

Reiterated

06/27/25

Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Gilead Sciences (GILD)

Richard NewitterTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/26/25

Truist Financial Remains a Buy on Kymera Therapeutics (KYMR)

Derek ArchilaWells Fargo

Wells Fargo

$57→$53

Buy

21.39%

Upside

Reiterated

06/26/25

Optimistic Outlook for Kymera Therapeutics Amid Strategic Partnerships and Strong KT-621 Prospects

Andrew FeinH.C. Wainwright

H.C. Wainwright

$54→$60

Buy

37.43%

Upside

Reiterated

06/26/25

Kymera Therapeutics price target raised to $60 from $54 at H.C. WainwrightKymera Therapeutics price target raised to $60 from $54 at H.C. Wainwright

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/26/25

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Jeff JonesOppenheimer

Oppenheimer

$56→$53

Buy

21.39%

Upside

Reiterated

06/26/25

Kymera Therapeutics price target lowered to $53 from $56 at OppenheimerKymera Therapeutics price target lowered to $53 from $56 at Oppenheimer

Faisal KhurshidLeerink Partners

Leerink Partners

$60

Buy

37.43%

Upside

Reiterated

06/25/25

Leerink Partners Remains a Buy on Kymera Therapeutics (KYMR)

Kelly ShiJefferies

Jefferies

$66→$64

Buy

46.59%

Upside

Reiterated

06/25/25

Kymera Therapeutics (KYMR) Receives a Buy from Jefferies

Eliana MerleUBS

UBS

$70

Buy

60.33%

Upside

Reiterated

06/03/25

UBS Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

1 Month

xxx

Success Rate

5/6 ratings generated profit

Average Return

+15.42%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 83.33% of your transactions generating a profit, with an average return of +15.42% per trade.

3 Months

xxx

Success Rate

8/12 ratings generated profit

Average Return

+33.02%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +33.02% per trade.

1 Year

Faisal KhurshidLeerink Partners

Success Rate

7/9 ratings generated profit

Average Return

+19.10%

reiterated a buy rating last month

Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +19.10% per trade.

2 Years

xxx

Success Rate

12/13 ratings generated profit

Average Return

+45.83%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +45.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KYMR has received 41 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 61.33.

Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$0.81 with a range of -$1.08 to -$0.31. The previous quarter’s EPS was -$0.82. KYMR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year KYMR has Preformed in-line its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $22.24M with a range of $0.00 to $62.50M. The previous quarter’s sales results were $22.10M. KYMR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year KYMR has Preformed in-line its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?

Based on analyst ratings, Kymera Therapeutics, Inc.’s 12-month average price target is 61.33.

What is KYMR’s upside potential, based on the analysts’ average price target?

Kymera Therapeutics, Inc. has 40.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KYMR a Buy, Sell or Hold?

Kymera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.

What is Kymera Therapeutics, Inc.’s price target?

The average price target for Kymera Therapeutics, Inc. is 61.33. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $53.00. The average price target represents 40.47% Increase from the current price of $43.66.

What do analysts say about Kymera Therapeutics, Inc.?

Kymera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of KYMR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

KYMR Analyst Ratings

KYMR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kymera Therapeutics

KYMR Analyst Recommendation Trends

KYMR Financial Forecast

KYMR Earnings Forecast

KYMR Sales Forecast

KYMR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts